TMX Newsfile·2026-01-20 23:05Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol, leading to inflated stock prices during the class period from April 1, 2024, to December 16, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen's management made positive assertions about the success of fasedienol based on prior clinical trial results, which misled investors [5]. - It is alleged that while promoting the drug's potential, the company concealed material adverse facts about the Phase 3 PALISADE-3 trial, resulting in shareholders purchasing stock at artificially inflated prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].